250 µCi quantities of Vasopressin (8-L-Arginine), [Phenylalanyl-3,4,5-3H(N)], are available for your research. Vasopressin binds and activates vasopressin receptors, a group of GPCRs that are potential drug targets for hyponatremia, congestive heart failure, and cirrhosis.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET800:

1. Lolait, S.J., O'Carroll, A.M., Mahan, L.C., et al. (1995) Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl. Acad. Sci. U.S.A., 92: 6783–6787.
2. Teitelbaum, I. and McGuinness, S. (1995) Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest., 96(1): 378–385.